HUTCHMED gets NMPA approval for ATLED in FGFR2 intrahepatic cholangiocarcinoma
Hutchmed announced NMPA approval for ATLED (fanregratinib) for treating FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma patients.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.